AR062258A1 - TIENO-PIRROL CONDENSED HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF HCV INFECTION - Google Patents
TIENO-PIRROL CONDENSED HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF HCV INFECTIONInfo
- Publication number
- AR062258A1 AR062258A1 ARP070103144A ARP070103144A AR062258A1 AR 062258 A1 AR062258 A1 AR 062258A1 AR P070103144 A ARP070103144 A AR P070103144A AR P070103144 A ARP070103144 A AR P070103144A AR 062258 A1 AR062258 A1 AR 062258A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heterocyclic
- alkyl
- heteroaryl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) o una sal o tautomero aceptable para uso farmacéutico del mismo: en donde: Y se selecciona entre el grupo que consiste en arilo, heteroarilo, arilo sustituido, y heteroarilo sustituido; HET se selecciona entre el grupo que consiste de un anillo arileno de 6 miembros, un anillo heteroarileno de 6 miembros que contiene 1, 2, o 3 heteroátomos seleccionados entre N, O, o S, y un anillo bicíclico de la formula (2) o (3) en donde HET se sustituye opcionalmente con (X)t, X se selecciona entre el grupo que consiste en alquilo, alquilo sustituido, alcoxi, alcoxi sustituido, amino, amino sustituido, halo, hidroxi, y nitro; t es un entero igual a 0, 1 o 2; W1, W4, y W5 son en forma independiente N o CH; W3 es N, CH, o es una union con la salvedad de que no más que un nitrogeno en el anillo bicíclico se oxida opcionalmente para formar un N-oxido; y cada línea punteada en forma independiente representa una union simple o doble entre los dos átomos unidos, con la salvedad de que cuando una de las líneas punteadas es una union simple, los dos átomos contiguos se sustituyen cada uno con 1 o 2 átomos de hidrogeno para satisfacer su valencia; uno de D o E es C-Ra y el otro de D o E es S; Ra y R se seleccionan en forma independiente entre el grupo que consiste de hidrogeno, alquilo, y alquilo sustituido; Q se selecciona entre el grupo que consiste en cicloalquilo, cicloalquilo sustituido, cicloalquenilo, cicloalquenilo sustituido, heterocíclico, heterocíclico sustituido, arilo, arilo sustituido, heteroarilo, y heteroarilo sustituido; y Z se selecciona entre el grupo que consiste en (a) carboxi y carboxi éster; (b) -C(X4)NR8R9, en donde X4 es =O, =NH, o =N-alquilo, R8 y R9 se seleccionan en forma independiente entre el grupo que consiste en hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico y heterocíclico sustituido o, como alternativa, R8 y R9 junto con el átomo de nitrogeno unido al mismo, forman un grupo anillo heterocíclico, heterocíclico sustituido, heteroarilo o heteroarilo sustituido; (c) -C(X3)NR21S(O)2R4, en donde X3 se selecciona entre =O, =NR24, y =S, en donde R24 es hidrogeno, alquilo, o alquilo sustituido; R4 se selecciona entre alquilo, alquilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico, heterocíclico sustituido, y NR22R23 en donde R21, R22 y R23 son en forma independiente hidrogeno, alquilo, alquilo sustituido, cicloalquilo, o cicloalquilo sustituido; o como alternativa, R21 y R22 o R22 y R23 junto con los átomos unidos al mismo se unen para formar un grupo heterocíclico opcionalmente sustituido; (d) -C(X2)-N(R3)CR2R2'C(=O)R1, en donde X2 se selecciona entre =O, =S, y =NR11, donde R11 es hidrogeno o alquilo, R1 se selecciona entre -OR7 y -NR8R9 donde R7 se selecciona entre hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico y heterocíclico sustituido; R8 y R9 son como se los define precedentemente; R2 y R2' se seleccionan en forma independiente entre hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, cicloalquilo, cicloalquilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico, y heterocíclico sustituido; o, como alternativa, R2 y R2' segun se han definido se toman junto con el átomo de carbono unido al mismo para formar un grupo cicloalquilo, cicloalquilo sustituido, heterocíclico o heterocíclico sustituido, o, como otra alternativa, uno de R2 o R2' es hidrogeno, alquilo o alquilo sustituido, y el otro se une, junto con el átomo de carbono unido al mismo, con el R7 o bien el átomo de oxígeno unido al mismo o R8 y el átomo de nitrogeno unido al mismo para formar un grupo heterocíclico o heterocíclico sustituido; R3 se selecciona entre hidrogeno y alquilo o, cuando R2 y R2' no se toman juntos para formar un anillo y cuando R2 o R2' y R7 o R8 no se unen para formar un grupo heterocíclico o heterocíclico sustituido, luego R3, junto con el átomo de nitrogeno unido al mismo, se puede tomar junto con uno de R2 y R2' para formar un grupo anillo heterocíclico o heterocíclico sustituido; (e) -C(X2)-N(R3)CR25R26R27, en donde X2 y R3 se definen precedentemente, y R25, R26 y R27se seleccionan en forma independiente entre el grupo que consiste de alquilo, alquilo sustituido, arilo, arilo sustituido, heterocíclico, heterocíclico sustituido, heteroarilo y heteroarilo sustituido, o R25 y R26 junto con el átomo de carbono unido al mismo forman un grupo cicloalquilo, cicloalquilo sustituido, heterocíclico o heterocíclico sustituido; y (f) un isostero de ácido carboxílico en donde dicho isostero no es como se lo define en (a)-(e).Claim 1: A compound characterized in that it responds to formula (1) or a salt or tautomer acceptable for pharmaceutical use thereof: wherein: Y is selected from the group consisting of aryl, heteroaryl, substituted aryl, and substituted heteroaryl; HET is selected from the group consisting of a 6-membered arylene ring, a 6-membered heteroarylene ring containing 1, 2, or 3 heteroatoms selected from N, O, or S, and a bicyclic ring of the formula (2) or (3) wherein HET is optionally substituted with (X) t, X is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, halo, hydroxy, and nitro; t is an integer equal to 0, 1 or 2; W1, W4, and W5 are independently N or CH; W3 is N, CH, or is a union with the proviso that no more than a nitrogen in the bicyclic ring is optionally oxidized to form an N-oxide; and each dotted line independently represents a single or double bond between the two atoms attached, with the proviso that when one of the dotted lines is a single bond, the two contiguous atoms are each substituted with 1 or 2 hydrogen atoms to satisfy its valence; one of D or E is C-Ra and the other of D or E is S; Ra and R are independently selected from the group consisting of hydrogen, alkyl, and substituted alkyl; Q is selected from the group consisting of cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and Z is selected from the group consisting of (a) carboxy and carboxy ester; (b) -C (X4) NR8R9, wherein X4 is = O, = NH, or = N-alkyl, R8 and R9 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, alkenyl substituted, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic or, alternatively, R8 and R9 together with the nitrogen atom attached thereto, form a heterocyclic ring group, substituted heterocyclic, heteroaryl or substituted heteroaryl; (c) -C (X3) NR21S (O) 2R4, wherein X3 is selected from = O, = NR24, and = S, wherein R24 is hydrogen, alkyl, or substituted alkyl; R4 is selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, and NR22R23 wherein R21, R22 and R23 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, or substituted cycloalkyl; or alternatively, R21 and R22 or R22 and R23 together with the atoms attached thereto join to form an optionally substituted heterocyclic group; (d) -C (X2) -N (R3) CR2R2'C (= O) R1, where X2 is selected from = O, = S, and = NR11, where R11 is hydrogen or alkyl, R1 is selected from - OR7 and -NR8R9 where R7 is selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic; R8 and R9 are as defined above; R2 and R2 'are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; or, alternatively, R2 and R2 'as defined are taken together with the carbon atom attached thereto to form a substituted cycloalkyl, substituted cycloalkyl, heterocyclic or heterocyclic group, or, as another alternative, one of R2 or R2' it is hydrogen, alkyl or substituted alkyl, and the other joins, together with the carbon atom attached thereto, with R7 or the oxygen atom attached thereto or R8 and the nitrogen atom attached thereto to form a group heterocyclic or substituted heterocyclic; R3 is selected from hydrogen and alkyl or, when R2 and R2 'are not taken together to form a ring and when R2 or R2' and R7 or R8 do not join to form a substituted heterocyclic or heterocyclic group, then R3, together with the Nitrogen atom attached thereto, can be taken together with one of R2 and R2 'to form a substituted heterocyclic or heterocyclic ring group; (e) -C (X2) -N (R3) CR25R26R27, wherein X2 and R3 are defined above, and R25, R26 and R27 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl and substituted heteroaryl, or R25 and R26 together with the carbon atom attached thereto form a cycloalkyl, substituted cycloalkyl, substituted heterocyclic or heterocyclic group; and (f) an isostero of carboxylic acid wherein said isostero is not as defined in (a) - (e).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83104006P | 2006-07-14 | 2006-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062258A1 true AR062258A1 (en) | 2008-10-29 |
Family
ID=38742551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103144A AR062258A1 (en) | 2006-07-14 | 2007-07-13 | TIENO-PIRROL CONDENSED HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF HCV INFECTION |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2044083A1 (en) |
JP (1) | JP2009543807A (en) |
KR (1) | KR20090033881A (en) |
CN (1) | CN101490058A (en) |
AR (1) | AR062258A1 (en) |
AU (1) | AU2007272441A1 (en) |
BR (1) | BRPI0714346A2 (en) |
CA (1) | CA2657651A1 (en) |
MX (1) | MX2009000513A (en) |
PE (1) | PE20080427A1 (en) |
RU (1) | RU2009105196A (en) |
TW (1) | TW200813070A (en) |
WO (2) | WO2008008907A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
ES2381410T3 (en) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Combination therapy for the treatment of HCV infections |
AR079528A1 (en) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | 5,5-FUSIONED ARYLENE OR HETEROARYLENE INHIBITORS OF HEPATITIS C VIRUS |
CN103649079B (en) * | 2010-12-22 | 2016-11-16 | Abbvie公司 | Hepatitis c inhibitor and application thereof |
US20120252721A1 (en) * | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
FR3008975A1 (en) * | 2013-07-23 | 2015-01-30 | Servier Lab | NOVEL PYRROLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
RU2546006C1 (en) | 2014-03-07 | 2015-04-10 | Римма Ильинична Ашкинази | Antiviral agent |
US10080728B2 (en) | 2015-01-20 | 2018-09-25 | Viktor Veniaminovich Tets | Hemostatic agent |
US10167293B2 (en) * | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
CA3064733A1 (en) | 2017-05-24 | 2018-11-29 | Viktor Veniaminovich Tets | Fractionated antimicrobial compositions and use thereof |
IL307203A (en) * | 2021-04-16 | 2023-11-01 | Gilead Sciences Inc | Thienopyrrole compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK288015B6 (en) * | 2001-06-11 | 2012-11-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
BRPI0410967A (en) * | 2003-06-04 | 2006-07-04 | Genelabs Tech Inc | compounds, compositions and their uses for the treatment of virus infections of the family flaviviridae |
-
2007
- 2007-07-12 CN CNA2007800266569A patent/CN101490058A/en active Pending
- 2007-07-12 EP EP07799544A patent/EP2044083A1/en not_active Withdrawn
- 2007-07-12 CA CA002657651A patent/CA2657651A1/en not_active Abandoned
- 2007-07-12 JP JP2009519699A patent/JP2009543807A/en active Pending
- 2007-07-12 WO PCT/US2007/073386 patent/WO2008008907A2/en active Application Filing
- 2007-07-12 KR KR1020097001707A patent/KR20090033881A/en not_active Application Discontinuation
- 2007-07-12 BR BRPI0714346-0A patent/BRPI0714346A2/en not_active Application Discontinuation
- 2007-07-12 WO PCT/US2007/073391 patent/WO2008008912A1/en active Application Filing
- 2007-07-12 AU AU2007272441A patent/AU2007272441A1/en not_active Abandoned
- 2007-07-12 MX MX2009000513A patent/MX2009000513A/en not_active Application Discontinuation
- 2007-07-12 RU RU2009105196/04A patent/RU2009105196A/en not_active Application Discontinuation
- 2007-07-13 PE PE2007000902A patent/PE20080427A1/en not_active Application Discontinuation
- 2007-07-13 TW TW096125693A patent/TW200813070A/en unknown
- 2007-07-13 AR ARP070103144A patent/AR062258A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20090033881A (en) | 2009-04-06 |
AU2007272441A1 (en) | 2008-01-17 |
JP2009543807A (en) | 2009-12-10 |
EP2044083A1 (en) | 2009-04-08 |
CN101490058A (en) | 2009-07-22 |
WO2008008912A1 (en) | 2008-01-17 |
CA2657651A1 (en) | 2008-01-17 |
TW200813070A (en) | 2008-03-16 |
PE20080427A1 (en) | 2008-06-11 |
BRPI0714346A2 (en) | 2013-03-19 |
MX2009000513A (en) | 2009-03-09 |
AU2007272441A2 (en) | 2009-03-19 |
WO2008008907A2 (en) | 2008-01-17 |
RU2009105196A (en) | 2010-08-27 |
WO2008008907A3 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062258A1 (en) | TIENO-PIRROL CONDENSED HETEROCICLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF HCV INFECTION | |
AR062827A1 (en) | POLYCLICAL VIRAL INHIBITORS, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF A VIRAL INFECTION MEDIATED BY THE VIRUS OF HEPATITIS C | |
AR066492A1 (en) | DERIVATIVES OF IMIDAZOQUINOLINE, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES FOR THE TREATMENT OF VIRAL, BACTERIAL, ALLERGIC AND DIFFERENT TYPES OF CANCERES. | |
AR041250A1 (en) | SULFONAMIDE DERIVATIVES AS INHIBITORS OF TNF-ALFA CONVERTER ENZYMES | |
CO6270320A2 (en) | USEFUL PIPERIDINE DERIVATIVES AS AN OREXINE RECEIVER ANTAGONISTS | |
CR8595A (en) | DIPEPTIDIL-PEPTIDASA INHIBITOR | |
PE20090511A1 (en) | IMIDAZOPYRIDINONES | |
AR044519A1 (en) | DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA | |
EA200800477A1 (en) | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | |
BRPI0707491B8 (en) | compounds useful as mineralocorticoid receptor modulating agents, said agents comprising the same and pharmaceutical compositions | |
AR056445A1 (en) | ARILIC AND HETEROARILIC DERIVATIVES OF 6 MEMBERS TO TREAT VIRUSES | |
GT200600134A (en) | NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES | |
AR064345A1 (en) | 8-OXOADENINE DERIVATIVES | |
EA200800478A1 (en) | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | |
UY29703A1 (en) | "MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS" | |
PE20090902A1 (en) | COMBINATION OF AN ANTIMITTIC AND AURORA KINASE INHIBITOR AS ANTI-CANCER AGENTS | |
ES2422204T3 (en) | Novel derivatives of imidazolidin-2-one as selective androgen receptor modulators (SARMS) | |
AR063458A1 (en) | INHIBITING PIRIDINE DERIVATIVES OF 11BETA HSD1 | |
BRPI0511933B8 (en) | quinazolinone derivatives, their use and preparation process, and pharmaceutical composition | |
AR079205A1 (en) | MORPHOLINOTIAZOLS AS POSITIVE ALOSTERIC MODULATORS ALFA 7 | |
PE20080608A1 (en) | CHEMICAL COMPOUNDS | |
AR077043A2 (en) | BICYCLE PYRIMIDINONES AND ITS USES | |
PE20140716A1 (en) | COMPOUNDS AND THEIR USES | |
AR069814A1 (en) | DERIVATIVES OF 4 AMINO-PYRIMIDINE, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
AR072045A1 (en) | UREA HETEROCICLIC DERIVATIVES AND METHODS TO USE THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |